Pituitary microadenomas: experience with Gd-DOTA-enhanced MR imaging at 0.5 Telsa

Eur J Radiol. 1994 Aug;18(3):185-90. doi: 10.1016/0720-048x(94)90332-8.

Abstract

Purpose: We report our experience with magnetic resonance imaging at 0.5 Tesla in the radiological diagnosis of pituitary adenomas.

Methods: Over 2 years we performed a prospective study in 38 patients with pituitary microadenomas to assess the potential additional benefit of gadolinium in the detection of small intrasellar lesions. The protocol included three coronal T1-weighted sequences: precontrast, early postcontrast (obtained less than 2 min after injection) and late postcontrast (obtained 5 min after injection). For each sequence lesions were classified according to their visibility into three categories: definite lesion, probable lesion or absent lesion.

Results: Lesions were classified as well-defined in 55% of patients on the precontrast study, 89.5% on the early postcontrast study and 60.5% on the late postcontrast study. Of nine microadenomas not detected on the precontrast scans, all were clearly seen on the early post contrast scans; only four were well-defined on the late postcontrast study. Only one lesion was not seen on the early postcontrast study but was well-defined on precontrast study as a spontaneous high-intensity focal area: it was a hemorrhagic microadenoma.

Conclusion: Our results suggest that the early postcontrast study is the most useful sequence for the detection of microadenomas. Precontrast image is necessary to detect hemorrhagic lesions; the late postcontrast sequence has a low additional diagnostic yield and seems unnecessary unless the other sequences are inconclusive.

MeSH terms

  • Adenoma / blood
  • Adenoma / diagnosis*
  • Adenoma / pathology
  • Adolescent
  • Adrenocorticotropic Hormone / metabolism
  • Adult
  • Contrast Media* / administration & dosage
  • Female
  • Gadolinium* / administration & dosage
  • Hemorrhage / diagnosis
  • Heterocyclic Compounds* / administration & dosage
  • Humans
  • Image Enhancement* / methods
  • Magnetic Resonance Imaging* / instrumentation
  • Magnetic Resonance Imaging* / methods
  • Male
  • Middle Aged
  • Organometallic Compounds* / administration & dosage
  • Pituitary Neoplasms / blood
  • Pituitary Neoplasms / diagnosis*
  • Pituitary Neoplasms / pathology
  • Prolactin / blood
  • Prolactinoma / pathology
  • Prospective Studies
  • Sella Turcica / pathology

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • Adrenocorticotropic Hormone
  • Prolactin
  • gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
  • Gadolinium